Int J Ophthalmol, Vol. 11, No. 8, Aug.18, 2018 www.ijo.cn Tel:8629-82245172 8629-82210956 Email:
[email protected]
·Brief Report·
Changes in interleukin-6 tear concentration and clinical outcome in moderate-to-severe bacterial corneal ulcers after corneal collagen cross-linking Marzarendra Dhion Erlangga1, Indra Tri Mahayana1, Jajah Fachiroh2, Angela Nurini Agni1, Agus Supartoto1, Suhardjo Pawiroranu1 1
Department of Ophthalmology, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada/Dr. Sardjito General Hospital, Yogyakarta 55284, Indonesia 2 Department of Biomolecular and Cell Biology, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Yogyakarta 55284, Indonesia Correspondence to: Agus Supartoto. Department of Ophthalmology, Faculty of Medicine, Universitas Gadjah Mada/ Dr.Sardjito General Hospital, Jl. Farmako, Sekip Utara, Yogyakarta 55284, Indonesia.
[email protected];
[email protected] Received: 2017-07-20 Accepted: 2018-01-23
blepharospasm (P=0.011) pre and post CXL. There was no significant decrease in conjunctival hyperemia pre and post CXL (P=0.293). There was significant reduction in IL-6 tear concentration and clinical improvement in moderateto-severe bacterial corneal ulcers which underwent CXL therapy. ● KEYWORDS: corneal ulcers; bacterial keratitis; collagen
cross-linking; interleukin-6
DOI:10.18240/ijo.2018.08.27 Citation: Erlangga MD, Mahayana IT, Fachiroh J, Agni AN, Supartoto A, Pawiroranu S. Changes in interleukin-6 tear concentration and clinical outcome in moderate-to-severe bacterial corneal ulcers after corneal
Abstract
collagen cross-linking. Int J Ophthalmol 2018;11(8):1421-1424
and clinical outcome in patients with moderate-to-severe
INTRODUCTION orneal ulcer or ulcerative keratitis is an inflammatory condition involving disruption of the epithelial lining and corneal stroma. Characteristic of corneal ulcers is its rapid progression; delayed management can lead to blindness. Corneal destruction can occur completely within 24-48h in highly virulent bacterial infections[1-3]. The incidence of corneal ulcers in developed countries is 2-11/100 000 per year, and tends to increase due to the use of contact lenses. The incidence in developing countries is much higher. A retrospective study in South India showed that the incidence of corneal ulcers was 113/100 000 per year[4]. In Nepal, the figure is estimated to reach 799/100 000 per year[5]. Bacterial keratitis is a vision-threatening and progressive condition; even with optimal management, the condition may still progress into ulceration, stromal abscess, even perforation. The difficulty in determining appropriate and effective antibiotic therapy leads to high rates of treatment failure. In cases of corneal ulcers that do not respond to antibiotic therapy, collagen cross-linking (CXL) is an adjuvant therapy option that promises good results[6-7]. In CXL, photoactivation of chromophores can have a disinfectant effect, resulting in reduced microbial counts. It is postulated that when light activates chromophore, there is intercalation between chromophore and nucleic acid from
● We aimed to evaluate interleukin-6 (IL-6) tear concentration bacterial corneal ulcers post corneal collagen cross-linking (CXL) therapy. This pre-post designed study involving 21 moderate-to-severe corneal ulcer patients who underwent CXL therapy. Patients with infectious corneal ulcer were given CXL therapy as adjunctive treatment after 5d of broadspectrum antibiotic treatment. Patients with moderate to severe infectious bacterial corneal ulcers were included in this study. Tear sampling was performed before CXL therapy, using sterile Schimer paper from conjunctival inferior fornix. CXL therapy was performed in accordance with the CXL Dresden protocol. Data recording and tear sampling were then performed at day 1 and day 7 after CXL therapy. Data recording included, presence of conjunctival hyperemia, visual analogue scale (VAS), size of corneal defects, and decemetocele. There was a decrease in IL-6 tear concentration by day 7 after CXL therapy (P=0.001). IL-6 concentration at 1h after therapy (2274.67±2120.46 pg/mL) tended to be lower than before therapy (4330.09±3169.70 pg/mL), but the difference was not statistically significant (P=0.821). The size of corneal defects decreased significantly post CXL (P=0.007). The logMAR visual acuity before and after CXL therapy was not found to be significantly different (P=0.277). There was a significant decrease in VAS values (P=0.018) and
C
1421
IL-6 in bacterial corneal ulcers after CXL
pathogens[8-10]. This leads to replication inhibition, thereby reducing the number of pathogens[7]. Immune responses and inflammatory processes in corneal ulcers are mediated by cytokines; interleukin-6 (IL-6) is one of the most common proinflamatory cytokines[11]. IL-6 is produced by corneal fibroblast cells around the site of injury. Increased IL-6 levels are associated with inflammatory processes, while decreased IL-6 levels are associated with improvements in inflammation and wound healing[12-13]. The purpose of this study was thus to investigate changes in IL-6 tear concentration and clinical conditions [such as size of corneal defect, descemetocele, logMAR visual acuity, visual analogue scale (VAS), blepharospasm, and conjunctival hyperemia] in patients with moderate-to-severe corneal ulcers which underwent CXL therapy. SUBJECTS AND METHODS Subjects This study used a pre-post design, involving 21 subjects with moderate-to-severe infectious bacterial corneal ulcers which underwent CXL during the study period at Dr. Sardjito General Hospital Yogyakarta; from January to June 2017. Patients with infectious corneal ulcer were given CXL therapy as adjunctive treatment after 5d broadspectrum antibiotic treatments (Ceftazidim and Vancomycin). The antibiotic treatment was then adjusted after the culture and antibiotic sensitivity test of corneal swab and scrapping was available (after 7d of treatment). The inclusion criteria in this study were all patients diagnosed wit moderate-to-severe bacterial corneal ulcers (moderate: 2-5 mm size and 20%-50% stromal depth; severe: size >5 mm and stromal depth >50%) indicated for CXL therapy; willing to do CXL therapy, willing to follow the research and signed the research informed consent sheet. Exclusion criteria in this study included patients who after CXL therapy refused to provide tear specimens as well as patients whose tear specimens were damaged or lost in the transport. Subjects who failed to follow the post CXL monitoring schedule were also excluded. Data Collection Tear sampling was performed before (pre), 1h after (peri) and 7d after (post) CXL therapy, using sterile Schimer paper, extracted from conjunctival inferior fornix. The primary outcome was IL-6 concentration in tears, obtained from ELISA results done at the Laboratory of Molecular Biology, Faculty of Medicine, Universitas Gadjah Mada, Indonesia. Clinical outcomes were size of corneal defects (clinically the ulcer size was observed 3 dimensionally, however for the objective data, the parameter was only 2 dimensional), presence of descemetocele, VAS, blepharospasm, and conjunctival hyperemia. The study followed the tenets of the Declaration of Helsinki. The Ethics Committee of the Faculty of Medicine, Universitas Gadjah Mada/Dr.Sardjito General Hospital approved the study protocol. After detailed explanation, informed consent was obtained from each patient prior to examination. 1422
Table 1 Characteristics of the study subjects Characteristics Age, y Mean±SD Range (min-max) Sex Male Female Size of corneal defect (mm2) Mean±SD Range (min-max) Visual acuity (logMAR) Mean±SD Range (min-max) VAS Mild (0-3) Moderate (4-6)
n (%) 43.86±16.55 17-69 13 (61.9) 8 (38.1) 36.32±25.59 6-100 2.12±0.22 1.48-2.30 14 (66.7) 7 (33.3)
IL-6: Interleukin-6; VAS: Visual analogue scale.
Statistical Analysis Statistical analysis was performed using SPSS 22.0 for Windows software. Data were expressed as mean±standard deviation (SD) and range, normality of all data samples was first confirmed by the Kolmogorov-Smirnov test. Difference in subject research characteristics were analyzed using the Chi-square test for categorical data and unpaired t test for numerical data if the distribution was normal, or MannWhitney test if the distribution was not normal. Changes in IL-6 concentration, average size of corneal defects, and visual acuity after CXL were analyzed using Wilcoxon signedrank test. Changes in VAS, blepharospasm, and conjunctival hyperemia were analyzed using Chi-square test. RESULTS Characteristics of the study subjects are listed in Table 1. We found that there was a significant decrease in tear IL-6 concentration pre and post CXL therapy, with differences 2055.43±2396.61 pg/mL (P=0.001). There was no statistically significant decrease in IL-6 concentration pre and peri CXL therapy, with differences 93.08±1885.50 pg/mL (P=0.821; Table 2). The mean size of corneal defects before and after CXL therapy also significantly reduced; pre CXL defect size was 36.32±25.59 mm2 and post CXL was 26.42±20.32 mm2 with differences is 9.90±14.37 mm2 (P=0.007). The mean visual acuity (logMAR) before and after CXL therapy in this study was not found to change significantly (pre CXL: 2.12±0.22 vs post CXL: 2.06±0.26; P=0.277; Table 3). Similar results were also obtained in previous studies by Vajpayee et al[9], where the mean visual acuity (logMAR) of pre CXL and post CXL was not statistically significant (P=0.46). This might due to healing of the cornea that results in scarring, thus still obscuring the visual axis[14]. There was a significant decrease in VAS values pre CXL and post CXL (P=0.018; Table 4). There was a statistically significant decrease in blepharospasm levels pre CXL and post CXL (P=0.011; Table 5).
Int J Ophthalmol, Vol. 11, No. 8, Aug.18, 2018 www.ijo.cn Tel:8629-82245172 8629-82210956 Email:
[email protected] Table 2 Changes in IL-6 tears concentration after CXL IL-6 (pg/mL)
Pre CXL
Mean±SD Range
Peri CXL
Post CXL
4330.09±3169.70
4237.02±3052.84
2274.67±2120.46
230.67-8230.67
126.67-8468.00
0-7217.33
a
P
0.821
a
Defference
93.08±1885.50
b
b
P
0.001
Defference
c
2055.43±2396.61
a
IL-6: Interleukin-6; CXL: Collagen cross-linking. Pre CXL vs Peri CXL; bPre CXL vs Post CXL; cP
